Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 20, Issue 6, Pages 513-529Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557519666191119144100
Keywords
Thiol; heavy metals; toxicity; radioprotectant; glutathione; antioxidant; chelation; ROS
Categories
Funding
- NEI of the National Institutes of Health [R15EY029813]
- Richard K. Vitek/FCR Endowment at Missouri University of Science and Technology
Ask authors/readers for more resources
The thiol (-SH) functional group is found in a number of drug compounds and confers a unique combination of useful properties. Thiol-containing drugs can reduce radicals and other toxic electrophiles, restore cellular thiol pools, and form stable complexes with heavy metals such as lead, arsenic, and copper. Thus, thiols can treat a variety of conditions by serving as radical scavengers, GSI I prodrugs, or metal chelators. Many of the compounds discussed here have been in use for decades, yet continued exploration of their properties has yielded new understanding in recent years, which can he used to optimize their clinical application and provide insights into the development of new treatments. The purpose of this narrative review is to highlight the biochemistry of currently used thiol drugs within the context of developments reported in the last five years. More specifically, this review focuses on thiol drugs that represent the standard of care for their associated conditions, including N-acerylcysteine, 2,3-meso-dimercaptosuccinic acid, British anti-Lessisite, D-penicillamine, amifostine, and others. Reports of novel dosing regimens, delivery strategies, and clinical applications for these compounds were examined with an eye toward emerging approaches to address a Wide range of medical conditions in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available